Adjunct therapy to prevent Clostridioides difficile infection (CDI) recurrence

Recurrent *Clostridioides difficile* infection (CDI) is a gastrointestinal complication defined by the re-emergence of diarrheal illness, colitis, and associated constitutional symptoms within two to eight weeks following the clinical resolution of an initial or prior episode

Recurrent *Clostridioides difficile* infection (CDI) is a gastrointestinal complication defined by the re-emergence of diarrheal illness, colitis, and associated constitutional symptoms within two to eight weeks following the clinical resolution of an initial or prior episode The condition is driven by profound dysbiosis of the colonic microbiota—typically triggered or exacerbated by antibacterial exposure—which results in the loss of colonization resistance, allowing persistent *C. difficile* s...

The condition is driven by profound dysbiosis of the colonic microbiota—typically triggered or exacerbated by antibacterial exposure—which results in the loss of colonization resistance, allowing persistent *C. difficile* spores to germinate and release mucosal toxins Clinically, these adjunct strategies focus on neutralizing enterotoxins or facilitating the restoration of intestinal microbial diversity to disrupt the cycle of repetitive, debilitating recurrences

The condition is driven by profound dysbiosis of the colonic microbiota—typically triggered or exacerbated by antibacterial exposure—which results in the loss of colonization resistance, allowing persistent *C. difficile* spores to germinate and release mucosal toxins

Adjunct therapy to prevent CDI recurrence is administered alongside or immediately following standard antibacterial regimens in populations at high risk for relapse, such as older adults, immunocompromised patients, or individuals with severe disease or multiple prior recurrences

Adjunct therapy to prevent CDI recurrence is administered alongside or immediately following standard antibacterial regimens in populations at high risk for relapse, such as older adults, immunocompromised patients, or individuals with severe disease or multiple prior recurrences

Adjunct therapy to prevent CDI recurrence is administered alongside or immediately following standard antibacterial regimens in populations at high risk for relapse, such as older adults, immunocompromised patients, or individuals with severe disease or multiple prior recurrences Clinically, these adjunct strategies focus on neutralizing enterotoxins or facilitating the restoration of intestinal microbial diversity to disrupt the cycle of repetitive, debilitating recurrences